株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の旅行用ワクチン市場:A型肝炎・日本脳炎・髄膜炎菌性髄膜炎ワクチンによる成長促進

Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth

発行 GBI Research 商品コード 189221
出版日 ページ情報 英文 116 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
世界の旅行用ワクチン市場:A型肝炎・日本脳炎・髄膜炎菌性髄膜炎ワクチンによる成長促進 Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth
出版日: 2013年05月14日 ページ情報: 英文 116 Pages
概要

世界の主要7ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国・日本)の旅行用ワクチン市場は、2012年に13億4300万米ドルの規模に達しました。2007年からの年平均(CAGR)成長率は11%、また2011年からの成長率は6.3%に達しています。また、2012〜2019年の市場成長率は年平均(CAGR)7.5%、2019年の市場規模は22億2400万米ドルと予想されています。

当レポートでは、世界の主要国における旅行用ワクチン(A型肝炎・日本脳炎などの予防接種用ワクチン)市場について調査し、ワクチン市場の全体的な収益動向や、地域別・治療分野別の詳細動向、製品パイプライン、参入企業の競合プロファイリング、M&A動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • ワクチンで予防できる疾患
    • ワクチンの種類
  • 各国の規制体制
  • ワクチンの製造工程

第4章 市場の特徴と予測

  • 収益予測
  • ワクチンの種類別の市場シェア
  • 地域別の市場シェア
  • 全世界の旅行者人口
  • 市場促進因子
    • 各国の人口高齢化と海外旅行者の増加
    • 新たなワクチン技術
    • 高リスク人口向けの新ワクチンの発売
  • 市場阻害因子
    • ワクチンの供給不足の問題
    • ワクチン生産に必要な、巨額の初期費用と特殊技術知識
    • 一般的な受容
    • 緊縮財政に伴う医療費支出の縮小

第5章 A型肝炎ワクチン

  • 疾患概要
  • 各国市場の予測
  • 各国のワクチン接種費用
  • パイプライン分析

第6章 B型肝炎ワクチン

  • 疾患概要
  • 各国市場の予測
  • 各国のワクチン接種費用
  • パイプライン分析

第7章 日本脳炎ワクチン

  • 疾患概要
  • 各国市場の予測
  • 各国のワクチン接種費用
  • パイプライン分析

第8章 髄膜炎菌性髄膜炎ワクチン

  • 疾患概要
  • 各国市場の予測
  • 各国のワクチン接種費用
  • パイプライン分析

第9章 狂犬病ワクチン

  • 疾患概要
  • 各国市場の予測
  • 各国のワクチン接種費用
  • パイプライン分析

第10章 腸チフスワクチン

  • 疾患概要
  • 各国市場の予測
  • 各国のワクチン接種費用
  • パイプライン分析

第11章 黄熱病ワクチン

  • 疾患概要
  • 各国市場の予測
  • 各国のワクチン接種費用
  • パイプライン分析

第12章 競合環境

  • イントロダクション
  • 主要企業のプロファイル
    • GlaxoSmithKline
    • Sanofi
    • Pfizer
    • Merck
    • Novartis

第13章 戦略的な業界再編の動向

  • 年度別
  • 種類別
  • 取引額別
  • 地域別
  • 主な企業合併・買収(M&A)取引の概要
  • 主なライセンシング取引の概要

第14章 アジア太平洋地域(インド・中国・オーストラリア)のワクチン市場:概況

  • インド
    • 規制体制
    • 主要企業のプロファイル
    • 近年の動向
  • 中国
    • 規制体制
    • 予防接種計画の拡大
    • 主要企業のプロファイル
  • オーストラリア
    • 規制体制
    • 指定ワクチンとその提供環境
    • 予防接種のスケジュール
    • 主要企業のプロファイル
    • 近年の動向
  • 新興国のワクチン市場:戦略的な企業統合の動向
  • 製品パイプライン(各相別)

第15章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC276MR

Summary

The leading business intelligence provider GBI Research has released its latest research report, entitled "Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth". The report provides insights into the vaccines in the Travel Vaccines market including market forecasts up to 2019. It provides an in-depth analysis of the travel vaccines, as well as insights into the Travel Vaccines R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Travel Vaccines market. The report analyzes the market for Travel Vaccines in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. In addition, it provides overview of vaccines market in India, China and Australia including regulatory frameworks and profiles of the top companies, deals and pipeline analysis. The report discusses the global pipeline for Travel Vaccines across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the Travel Vaccines market in the top seven markets was valued at $1,343m in 2012, increasing at a Compound Annual Growth Rate (CAGR) of 11% during the 2007-2012 historic period. The market is projected to witness growth of 7.5% during the 2012-2019 forecast period to reach $2,224m. The growth in the Travel Vaccines market is driven by increased uptake of hepatitis A vaccines, which is expected to grow at a CAGR of 7% during the forecast period and reach $423m in 2019 from $264m in 2012.

Scope

  • Annualized market data for the Travel Vaccines market from 2007 to 2012, forecast forward to 2019.
  • Analysis of the Travel Vaccines market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Market characterization of the Travel Vaccines market including market size, cost of vaccination.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of vaccine development.
  • Competitive benchmarking of leading companies. Key companies studied in this report are GlaxoSmithKline, Sanofi, Pfizer, Merck and Novartis.
  • Key M&A activities and licensing agreements that have taken place between 2009 and up to January 2013 in the global Travel Vaccines market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and Travel Vaccines market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the global Travel Vaccines market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Executive Summary

The Travel Vaccines Market is Forecast to Grow at a CAGR of 7.5% from 2012 to 2019

GBI Research estimated the travel vaccines market in the top seven markets (comprising the US, the UK, Spain, Italy, France, Germany and Japan) to be worth $1,343m in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 11% from 2007. The Year-on-Year (YoY) market growth was 6.3%, with revenue of $1,264m in 2011. It is expected to reach $2,224m by 2019, having grown at a CAGR of 7.5% from 2012.

The hepatitis A travel vaccines market in the top seven markets was worth $264m in 2012 and is expected to reach $423m by 2019 at a CAGR of 7%. The meningococcal travel vaccines market accounted for $225m in 2012 and is expected to reach $406m by 2019 at a CAGR of 8.8%. The Japanese Encephalitis (JE) travel vaccines market accounted for $234m in 2012 and is expected to reach $283m by 2019 at a CAGR of 2.7%.

A Strong Pipeline in which Nearly 30% of Vaccine Candidates are in Phase III and Phase II

The global travel-vaccine pipeline appears very strong, with 18% of candidates in Phase II, 13% in Phase I, 11% in Phase III and 5% registration-filed.

Vaccine companies manage their R&D portfolio by balancing investment between novel, innovative targets with the potential to have a major impact on human health; developing best-in-class approaches; and delivering the maximum value of approved vaccines through new indications and formulations. Developing a new vaccine product is a costly, lengthy and uncertain process, and a new candidate can fail at any stage of the development process or fail to receive regulatory approval. However, vaccines' ability to generate high revenues and profits despite being priced at a premium has proven attractive to existing players in the market and to big pharmaceutical companies, who have been watching development with interest.

Hepatitis A Vaccines, Japanese Encephalitis Vaccines and Meningococcal Vaccines Account for More than Half of the Market

Hepatitis A vaccines led the market in 2012 with a share of 20%, followed by JE vaccines and meningococcal vaccines with 17% each.

Hepatitis A vaccines are commonly used prominent travel vaccines, and the increase in global tourist traffic has increased their use, in turn driving the market. Vaccines for hepatitis A provide immunity for approximately 15-20 years, rather than being lifelong, which is expected to drive future growth.

Table of Contents

1 Table of Contents 6

  • 1.1 List of Tables 10
  • 1.2 List of Figures 12

2 Travel Vaccines Market to 2019: Introduction 14

  • 2.1 Overview 14

3 Travel Vaccines Market to 2019: Overview 15

  • 3.1 Vaccine-Preventable Diseases 15
    • 3.1.1 Types of Vaccines 16
  • 3.2 Regulatory Framework 17
    • 3.2.1 US 17
    • 3.2.2 UK 17
    • 3.2.3 France 18
    • 3.2.4 Germany 18
    • 3.2.5 Italy 18
    • 3.2.6 Spain 19
    • 3.2.7 Japan 19
  • 3.3 Vaccine Manufacturing Process 20

4 Travel Vaccines Market to 2019: Market Characterization and Forecast 21

  • 4.1 Revenue Forecast 21
  • 4.2 Market Share by Vaccine Type 22
  • 4.3 Market Share by Geography 23
  • 4.4 Traveling Population 24
  • 4.5 Drivers 25
    • 4.5.1 Aging Population and Increase in Global Tourist Traffic 25
    • 4.5.2 Novel Vaccine Technologies 25
    • 4.5.3 New and Novel Vaccines Launches Targeting High-Risk Populations 25
  • 4.6 Restraints 26
    • 4.6.1 Vaccine Supply Shortage Issues 26
    • 4.6.2 High Start-up Costs and Special Technical Expertise Requirements for Vaccine Production 26
    • 4.6.3 Public Acceptance 26
    • 4.6.4 Austerity Measures Leading to a Drop in Healthcare Funding 26

5 Travel Vaccines Market to 2019: Hepatitis A Vaccines 27

  • 5.1 Disease Overview 27
  • 5.2 Market Forecasts 28
    • 5.2.1 US 28
    • 5.2.2 Top Five European Countries 29
    • 5.2.3 Japan 30
  • 5.3 Cost of Vaccination 31
    • 5.3.1 US 31
    • 5.3.2 Top Five European Countries 31
    • 5.3.3 Japan 32
  • 5.4 Pipeline Analysis 32
    • 5.4.1 Phase III (Inactive) 33
    • 5.4.2 Preclinical and Discovery (Inactive) 33

6 Travel Vaccines Market to 2019: Hepatitis B Vaccines 34

  • 6.1 Disease Overview 34
  • 6.2 Market Forecasts 35
    • 6.2.1 US 35
    • 6.2.2 Top Five European Countries 36
    • 6.2.3 Japan 37
  • 6.3 Cost of Vaccination 38
    • 6.3.1 US 38
    • 6.3.2 Top Five European Countries 38
    • 6.3.3 Japan 39
  • 6.4 Pipeline Analysis 39
    • 6.4.1 Registration and Phase III 40
    • 6.4.2 Phase II 40
    • 6.4.3 Phase I 40
    • 6.4.4 Preclinical and Discovery 41

7 Travel Vaccines Market to 2019: Japanese Encephalitis Vaccines 42

  • 7.1 Disease Overview 42
  • 7.2 Market Forecasts 43
    • 7.2.1 US 43
    • 7.2.2 Top Five European Countries 44
    • 7.2.3 Japan 45
  • 7.3 Cost of Vaccination 46
    • 7.3.1 US 46
    • 7.3.2 Top Five European Countries 46
    • 7.3.3 Japan 47
  • 7.4 Pipeline Analysis 47
    • 7.4.1 Registration 48
    • 7.4.2 Preclinical and Discovery 48

8 Travel Vaccines Market to 2019: Meningococcal Vaccines 49

  • 8.1 Disease Overview 49
  • 8.2 Market Forecasts 50
    • 8.2.1 US 50
    • 8.2.2 Top Five European Countries 51
  • 8.3 Cost of Vaccination 52
    • 8.3.1 US 52
    • 8.3.2 Top Five European Countries 52
  • 8.4 Pipeline Analysis 53
    • 8.4.1 Registration and Phase III 53
    • 8.4.2 Phase II 54
    • 8.4.3 Preclinical and Discovery 54

9 Travel Vaccines Market to 2019: Rabies Vaccines 55

  • 9.1 Disease Overview 55
  • 9.2 Market Forecasts 56
    • 9.2.1 US 56
    • 9.2.2 Top Five European Countries 57
    • 9.2.3 Japan 58
  • 9.3 Cost of Vaccination 59
    • 9.3.1 US 59
    • 9.3.2 Top Five European Countries 59
    • 9.3.3 Japan 60
  • 9.4 Pipeline Analysis 60
    • 9.4.1 Phase II 61
    • 9.4.2 Phase I 61
    • 9.4.3 Preclinical 61

10 Travel Vaccines Market to 2019: Typhoid Vaccines 62

  • 10.1 Disease Overview 62
  • 10.2 Market Forecasts 63
    • 10.2.1 US 63
    • 10.2.2 Top Five European Countries 64
  • 10.3 Cost of Vaccination 65
    • 10.3.1 US 65
    • 10.3.2 Top Five European Countries 65
  • 10.4 Pipeline Analysis 66
    • 10.4.1 Phase II 66
    • 10.4.2 Preclinical 66

11 Travel Vaccines Market to 2019: Yellow Fever Vaccines 67

  • 11.1 Disease Overview 67
  • 11.2 Market Forecasts 68
    • 11.2.1 US 68
    • 11.2.2 Top Five European Countries 69
    • 11.2.3 Japan 70
  • 11.3 Cost of Vaccination 71
    • 11.3.1 US 71
    • 11.3.2 Top Five European Countries 71
    • 11.3.3 Japan 72
  • 11.4 Pipeline Analysis 72
    • 11.4.1 Phase III 73
    • 11.4.2 Phase I 73
    • 11.4.3 Preclinical and Discovery 73

12 Travel Vaccines Market to 2019: Competitive Landscape 74

  • 12.1 Introduction 74
  • 12.2 Major Company Profiles 74
    • 12.2.1 GlaxoSmithKline 74
    • 12.2.2 Sanofi 76
    • 12.2.3 Pfizer 77
    • 12.2.4 Merck 78
    • 12.2.5 Novartis 79

13 Travel Vaccines Market to 2019: Strategic Consolidations 80

  • 13.1 Deals by Year 80
  • 13.2 Deals by Type 81
  • 13.3 Deals by Value 82
  • 13.4 Deals by Geography 83
  • 13.5 Summary of Major M&A Deals 83
    • 13.5.1 Gilead Sciences Completes Acquisition of Pharmasset for $11.2 Billion 83
    • 13.5.2 Johnson & Johnson Acquires Crucell 84
  • 13.6 Summary of Major Licensing Deals 84
    • 13.6.1 Intercell Enters into Licensing Agreement with Novartis for IC51 84
    • 13.6.2 Gilead Sciences Enters into Licensing Agreement with GlobeImmune 84

14 Vaccines in Asia-Pacific - India, China and Australia: Overview 85

  • 14.1 India 85
    • 14.1.1 Regulatory Framework 85
    • 14.1.2 Major Company Profiles 91
  • 14.2 Recent Developments 92
    • 14.2.1 Biological E. Launches Japanese Encephalitis Vaccine Jeev in India - September 2012 92
    • 14.2.2 Approvals by Central Drugs Standard Control Organization 92
  • 14.3 China 92
    • 14.3.1 Regulatory Framework 92
    • 14.3.2 Expanded Programme on Immunization 94
    • 14.3.3 Major Company Profiles 95
  • 14.4 Australia 97
    • 14.4.1 Regulatory Framework 97
    • 14.4.2 Designated Vaccines and Circumstances in which Vaccines may be Provided 98
    • 14.4.3 Immunization Schedule 104
    • 14.4.4 Major Company Profiles 105
    • 14.4.5 Recent Developments 106
  • 14.5 Vaccines in Emerging Markets: Strategic Consolidations 107
    • 14.5.1 Deals by Year 107
    • 14.5.2 Deals by Type 108
    • 14.5.3 Deals by Value 109
  • 14.6 Vaccines in Emerging Markets: Pipeline by Phase 110

15 Travel Vaccines Market to 2019: Appendix 111

  • 15.1 Market Definitions 111
  • 15.2 Abbreviations 111
  • 15.3 Bibliography 112
  • 15.4 Research Methodology 113
    • 15.4.1 Coverage 113
    • 15.4.2 Secondary Research 113
    • 15.4.3 Primary Research 114
    • 15.4.4 Model for Estimation of Vaccine Market 114
  • 15.5 Geographical Landscape 116
  • 15.6 Pipeline Analysis 116
  • 15.7 Competitive Landscape 116
    • 15.7.1 Expert Panel Validation 116
  • 15.8 Contact Us 116
  • 15.9 Disclaimer 116

List of Tables

  • Table 1: Travel Vaccines Market, Top Seven Markets, Vaccine-Preventable Diseases, 2012 15
  • Table 2: Travel Vaccines Market, Top Seven Markets, Traveler Population (million), 2007-2012 24
  • Table 3: Travel Vaccines Market, Top Seven Markets, Traveler Population Forecast (million), 2012-2019 25
  • Table 4: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue ($m), 2007-2012 28
  • Table 5: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue Forecast ($m), 2012-2019 28
  • Table 6: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue ($m), 2007-2012 29
  • Table 7: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue Forecast ($m), 2012-2019 29
  • Table 8: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue ($m), 2007-2012 30
  • Table 9: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue Forecast ($m), 2012-2019 30
  • Table 10: Travel Vaccines Market, US, Hepatitis A Vaccines, Cost ($), 2007-2012 31
  • Table 11: Travel Vaccines Market, US, Hepatitis A Vaccines, Cost ($), 2012-2019 31
  • Table 12: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Cost ($), 2007-2012 31
  • Table 13: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Cost Forecast ($), 2012-2019 31
  • Table 14: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Cost ($), 2007-2012 32
  • Table 15: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Cost Forecast ($), 2012-2019 32
  • Table 16: Travel Vaccines Market, Global, Hepatitis A Vaccines, Phase III (Inactive) Pipeline, 2012 33
  • Table 17: Travel Vaccines Market, Global, Hepatitis A Vaccines, Preclinical and Discovery (Inactive) Pipeline, 2012 33
  • Table 18: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue ($m), 2007-2012 35
  • Table 19: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue Forecast ($m), 2012-2019 35
  • Table 20: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue ($m), 2007-2012 36
  • Table 21: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue Forecast ($m), 2012-2019 36
  • Table 22: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue ($m), 2007-2012 37
  • Table 23: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue Forecast ($m), 2012-2019 37
  • Table 24: Travel Vaccines Market, US, Hepatitis B Vaccines, Cost ($), 2007-2012 38
  • Table 25: Travel Vaccines Market, US, Hepatitis B Vaccines, Cost Forecast ($), 2012-2019 38
  • Table 26: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Cost ($), 2007-2012 38
  • Table 27: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Cost ($), 2012-2019 38
  • Table 28: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Cost ($), 2007-2012 39
  • Table 29: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Cost Forecast ($), 2012-2019 39
  • Table 30: Travel Vaccines Market, Global, Hepatitis B Vaccines, Registration and Phase III Pipeline, 2012 40
  • Table 31: Travel Vaccines Market, Global, Hepatitis B Vaccines, Phase II Pipeline, 2012 40
  • Table 32: Travel Vaccines Market, Global, Hepatitis B Vaccines, Phase I Pipeline, 2012 40
  • Table 33: Travel Vaccines Market, Global, Hepatitis B Vaccines, Preclinical and Discovery Pipeline, 2012 41
  • Table 34: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue ($m), 2007-2012 43
  • Table 35: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2012-2019 43
  • Table 36: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Revenue ($m), 2007-2012 44
  • Table 37: Travel Vaccines Market to 2019, Japanese Encephalitis Vaccines, Top Five European Countries, Revenue Forecast ($m), 2012-2019 44
  • Table 38: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue ($m), 2007-2012 45
  • Table 39: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2012-2019 45
  • Table 40: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Cost ($), 2007-2012 46
  • Table 41: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012-2019 46
  • Table 42: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Cost ($), 2007-2012 46
  • Table 43: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012-2019 46
  • Table 44: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Cost ($), 2007-2012 47
  • Table 45: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012-2019 47
  • Table 46: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Registration, 2012 48
  • Table 47: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Preclinical and Discovery, 2012 48
  • Table 48: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue ($m), 2007-2012 50
  • Table 49: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue Forecast ($m), 2012-2019 50
  • Table 50: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue ($m), 2007-2012 51
  • Table 51: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue Forecast ($m), 2012-2019 51
  • Table 52: Travel Vaccines Market, US, Meningococcal Vaccines, Cost ($), 2007-2012 52
  • Table 53: Travel Vaccines Market, US, Meningococcal Vaccines, Cost Forecast ($), 2012-2019 52
  • Table 54: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Cost ($), 2007-2012 52
  • Table 55: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Cost Forecast ($), 2012-2019 52
  • Table 56: Travel Vaccines Market, Global, Meningococcal Vaccines, Registration and Phase III Pipeline, 2012 53
  • Table 57: Travel Vaccines Market, Global, Meningococcal Vaccines, Phase II Pipeline, 2012 54
  • Table 58: Travel Vaccines Market, Global, Meningococcal Vaccines, Preclinical Pipeline, 2012 54
  • Table 59: Travel Vaccines Market, US, Rabies Vaccines, Revenue ($m), 2007-2012 56
  • Table 60: Travel Vaccines Market, US, Rabies Vaccines, Revenue Forecast ($m), 2012-2019 56
  • Table 61: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue ($m), 2007-2012 57
  • Table 62: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue Forecast ($m), 2012-2019 57
  • Table 63: Travel Vaccines Market, Japan, Rabies Vaccines, Revenue ($m), 2007-2012 58
  • Table 64: Travel Vaccines Market, Japan, Rabies Vaccines, Revenue Forecast ($m), 2012-2019 58
  • Table 65: Travel Vaccines Market, US, Rabies Vaccines, Cost ($), 2007-2012 59
  • Table 66: Travel Vaccines Market, US, Rabies Vaccines, Cost Forecast ($), 2012-2019 59
  • Table 67: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Cost ($), 2007-2012 59
  • Table 68: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Cost Forecast ($), 2012-2019 59
  • Table 69: Travel Vaccines Market, Japan, Rabies Vaccines, Cost ($), 2007-2012 60
  • Table 70: Travel Vaccines Market, Japan. Rabies Vaccines, Cost Forecast ($), 2012-2019 60
  • Table 71: Travel Vaccines Market, Global, Rabies Vaccines, Phase II Pipeline, 2012 61
  • Table 72: Travel Vaccines Market, Global, Rabies Vaccines, Phase I Pipeline, 2012 61
  • Table 73: Travel Vaccines Market, Global, Rabies Vaccines, Preclinical Pipeline, 2012 61
  • Table 74: Travel Vaccines Market, US, Typhoid Vaccines, Revenue ($m), 2007-2012 63
  • Table 75: Travel Vaccines Market, US, Typhoid Vaccines, Revenue Forecast ($m), 2012-2019 63
  • Table 76: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue ($m), 2007-2012 64
  • Table 77: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue Forecast ($m), 2012-2019 64
  • Table 78: Travel Vaccines Market, US, Typhoid Vaccines, Cost ($), 2007-2012 65
  • Table 79: Travel Vaccines Market, US, Typhoid Vaccines, Cost Forecast ($), 2012-2019 65
  • Table 80: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Cost ($), 2007-2012 65
  • Table 81: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Cost Forecast ($), 2012-2019 65
  • Table 82: Travel Vaccines Market, Global, Typhoid Vaccines, Phase II Pipeline, 2012 66
  • Table 83: Travel Vaccines Market, Global, Typhoid Vaccines, Preclinical Pipeline, 2012 66
  • Table 84: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue ($m), 2007-2012 68
  • Table 85: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue Forecast ($m), 2012-2019 68
  • Table 86: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue ($m), 2007-2012 69
  • Table 87: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue Forecast ($m), 2012-2019 69
  • Table 88: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue ($m), 2007-2012 70
  • Table 89: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue Forecast ($m), 2012-2019 70
  • Table 90: Travel Vaccines Market, US, Yellow Fever Vaccines, Cost ($), 2007-2012 71
  • Table 91: Travel Vaccines Market, US, Yellow Fever Vaccines, Cost Forecast ($), 2012-2019 71
  • Table 92: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Cost ($), 2007-2012 71
  • Table 93: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Cost Forecast ($), 2012-2019 71
  • Table 94: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Cost ($), 2007-2012 72
  • Table 95: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Cost Forecast ($), 2012-2019 72
  • Table 96: Travel Vaccines Market, Global, Yellow Fever Vaccines, Phase III, 2012 73
  • Table 97: Travel Vaccines Market, Global, Yellow Fever Vaccines, Phase I, 2012 73
  • Table 98: Travel Vaccines Market, Global, Yellow Fever Vaccines, Preclinical and Discovery, 2012 73
  • Table 99: Travel Vaccines Market, India, Immunization Schedule, 2012 87
  • Table 100: Travel Vaccines Market, India, Major Vaccine Brands by Indication, 2012 88
  • Table 101: Travel Vaccines Market, China, Policies, 2012 95
  • Table 102: Travel Vaccines Market, Australia, Designated Bacterial Vaccines and Circumstances in which Vaccines may be Provided, 2011 98
  • Table 103: Travel Vaccines Market, Australia, Designated Viral Vaccines and Circumstances in which Vaccines may be Provided, 2011 100
  • Table 104: Travel Vaccines Market, Australia, Designated Combined Bacterial and Viral Vaccines and Circumstances in which Vaccines may be Provided, 2011 103
  • Table 105: Travel Vaccines Market, Australia, Immunization Schedule, 2012 104
  • Table 106: Travel Vaccines Market, Emerging Markets, Pipeline by Phase, 2012 110

List of Figures

  • Figure 1: Travel Vaccines Market, Global, Vaccine Types, 2012 16
  • Figure 2: Travel Vaccines Market, Global, Vaccine Manufacturing Process, 2012 20
  • Figure 3: Travel Vaccines Market, Top Seven Markets, Revenue Forecast ($m), 2007-2019 21
  • Figure 4: Travel Vaccines Market, Top Seven Markets, Market Share by Vaccine Type (%), 2012 22
  • Figure 5: Travel Vaccines Market, Top Seven Markets, Market Share by Geography (%), 2012 23
  • Figure 6: Travel Vaccines Market, Top Seven Markets, Traveling Population (million), 2007-2019 24
  • Figure 7: Travel Vaccines Market, Global, Geographical Distribution of Hepatitis A, 2012 27
  • Figure 8: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue Forecast ($m), 2007-2019 28
  • Figure 9: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue Forecast ($m), 2007-2019 29
  • Figure 10: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue Forecast ($m), 2007-2019 30
  • Figure 11: Travel Vaccines Market, Global, Hepatitis A Vaccines, Pipeline by Phase (%), 2012 32
  • Figure 12: Travel Vaccines Market, Global, Geographical Distribution of Hepatitis B, 2012 34
  • Figure 13: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue Forecast ($m), 2007-2019 35
  • Figure 14: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue Forecast ($m), 2007-2019 36
  • Figure 15: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue Forecast ($m), 2007-2019 37
  • Figure 16: Travel Vaccines Market, Global, Hepatitis B Vaccines, Pipeline by Phase (%), 2012 39
  • Figure 17: Travel Vaccines Market, Global, Geographical Distribution of Japanese Encephalitis, 2012 42
  • Figure 18: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007-2019 43
  • Figure 19: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007-2019 44
  • Figure 20: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007-2019 45
  • Figure 21: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Pipeline by Phase (%), 2012 47
  • Figure 22: Travel Vaccines Market, Global, Geographical Distribution of Meningococcal Meningitis, 2012 49
  • Figure 23: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue Forecast ($m), 2007-2019 50
  • Figure 24: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue Forecast ($m), 2007-2019 51
  • Figure 25: Travel Vaccines Market, Global, Meningococcal Vaccines, Pipeline by Phase (%), 2012 53
  • Figure 26: Travel Vaccines Market, Global, Geographical Distribution of Rabies, 2012 55
  • Figure 27: Travel Vaccines Market, US, Rabies Vaccines, Revenue Forecast ($m), 2007-2019 56
  • Figure 28: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue Forecast ($m), 2007-2019 57
  • Figure 29: Travel Vaccines Market, Japan. Rabies Vaccines, Revenue Forecast ($m), 2007-2019 58
  • Figure 30: Travel Vaccines Market, Global, Rabies Vaccines, Pipeline by Phase (%), 2012 60
  • Figure 31: Travel Vaccines Market, Global, Geographical Distribution of Typhoid, 2012 62
  • Figure 32: Travel Vaccines Market, US, Typhoid Vaccines, Revenue Forecast ($m), 2007-2019 63
  • Figure 33: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue Forecast ($m), 2007-2019 64
  • Figure 34: Travel Vaccines Market, Global, Typhoid Vaccines, Pipeline by Phase (%), 2012 66
  • Figure 35: Travel Vaccines Market, Global, Geographical Distribution of Yellow Fever, 2012 67
  • Figure 36: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue Forecast ($m), 2007-2019 68
  • Figure 37: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue Forecast ($m), 2007-2019 69
  • Figure 38: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue Forecast ($m), 2007-2019 70
  • Figure 39: Travel Vaccines Market, Global, Yellow Fever Vaccines, Pipeline by Phase (%), 2012 72
  • Figure 40: GlaxoSmithKline, Travel Vaccines Market, SWOT Analysis, 2012 75
  • Figure 41: Sanofi, Travel Vaccines Market, SWOT Analysis, 2012 76
  • Figure 42: Pfizer, Travel Vaccines Market, SWOT Analysis, 2012 77
  • Figure 43: Merck, Travel Vaccines Market, SWOT Analysis, 2012 78
  • Figure 44: Novartis, Travel Vaccines Market, SWOT Analysis, 2012 79
  • Figure 45: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Year, 2009-2013 80
  • Figure 46: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Type, 2008-2013 81
  • Figure 47: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Value, 2008-2013 82
  • Figure 48: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Geography, 2008-2013 83
  • Figure 49: Vaccines in Emerging Markets, India, National Rural Health Mission, 2011 86
  • Figure 50: Vaccines in Emerging Markets, Deals by Year, 2009-2013 107
  • Figure 51: Travel Vaccines Market, Emerging Markets, Deals by Type (%), 2009-2013 108
  • Figure 52: Travel Vaccines Market, Emerging Markets, Deals by Value ($m), 2009-2013 109
  • Figure 53: Travel Vaccines Market, Emerging Markets, Pipeline by Phase (%), 2012 110
  • Figure 54: GBI Research Market Forecasting Model 115
Back to Top